Shots:
- Alvotech has reported the launch of Gobivaz (AVT05), a biosimilar version of Simponi (golimumab) for the treatment of several chronic inflammatory diseases, with commercialization led by Advanz Pharma
- In the UK, Gobivaz’s launch is supported by an NHS England tender award, while rollout across EEA markets will advance in line with country-specific pricing, reimbursement & market access processes; it is offered in identical dosage forms & presentations & manufactured at Alvotech’s Iceland facility
- Gobivaz is an IgG1 anti-TNF-α monoclonal antibody that received EC approval, supported by robust analytical, preclinical & clinical data demonstrating biosimilarity to Simponi
Ref: Globenewswire | Image: Alvotech |Press Release
Related News: Alvotech Reports the EC Approval of AVT03 (Biosimilar, Prolia and Xgeva)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
